73 related articles for article (PubMed ID: 38714753)
1. m6ACali: machine learning-powered calibration for accurate m6A detection in MeRIP-Seq.
Ye H; Li T; Rigden DJ; Wei Z
Nucleic Acids Res; 2024 May; 52(9):4830-4842. PubMed ID: 38634812
[TBL] [Abstract][Full Text] [Related]
2. Alteration of RNA m6A methylation mediates aberrant RNA binding protein expression and alternative splicing in condyloma acuminatum.
Liu X; Xie B; Wang S; Wu Y; Zhang Y; Ruan L
PeerJ; 2024; 12():e17376. PubMed ID: 38784389
[TBL] [Abstract][Full Text] [Related]
3. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
Zhang Y; Ling Y; Zhou Y; Shi X; Shen F; Zhou J; Chen Y; Yang F; Gu Y; Wang J
Cancer Control; 2024; 31():10732748241256819. PubMed ID: 38755968
[TBL] [Abstract][Full Text] [Related]
4. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract][Full Text] [Related]
5. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
[TBL] [Abstract][Full Text] [Related]
6. Epitranscriptome profiling of spleen mRNA m
Wang L; Wu J; Liu R; Chen W; Pang Z; Zhou F; Xia L; Huang J; Pan T; Su XZ; Wang X
Front Immunol; 2022; 13():998756. PubMed ID: 36203583
[No Abstract] [Full Text] [Related]
7. Dysregulated N
He D; Yang X; Liu L; Shen D; Liu Q; Liu M; Zhang X; Cui L
Front Med; 2024 Apr; 18(2):285-302. PubMed ID: 38491210
[TBL] [Abstract][Full Text] [Related]
8. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.
Han X; Gao Y; Jiang M; Li Z; Guo J; Li Y; Yi J; Hou L; Cheng J; Feng L; Jin Y; Zhao X; Yue W
J Cancer; 2024; 15(11):3427-3440. PubMed ID: 38817863
[No Abstract] [Full Text] [Related]
9. Boosting edgeR (Robust) by dealing with missing observations and gene-specific outliers in RNA-Seq profiles and its application to explore biomarker genes for diagnosis and therapies of ovarian cancer.
Sarker B; Matiur Rahaman M; Alamin MH; Ariful Islam M; Nurul Haque Mollah M
Genomics; 2024 May; 116(3):110834. PubMed ID: 38527595
[TBL] [Abstract][Full Text] [Related]
10. IGF2BP2-Shox2 axis regulates hippocampal-neuronal senescence to alleviate microgravity-induced recognition disturbance.
Zhao Y; Ji G; Zhou S; Cai S; Li K; Zhang W; Zhang C; Yan N; Zhang S; Li X; Song B; Qu L
iScience; 2024 Jun; 27(6):109917. PubMed ID: 38812544
[TBL] [Abstract][Full Text] [Related]
11. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
[TBL] [Abstract][Full Text] [Related]
12. Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment.
Huang J; Zhou L; Deng K
J Ovarian Res; 2023 Apr; 16(1):64. PubMed ID: 37005667
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
Wu J; Wang X; Li X
Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
[TBL] [Abstract][Full Text] [Related]
14. FTO Inhibits Epithelial Ovarian Cancer Progression by Destabilising SNAI1 mRNA through IGF2BP2.
Sun M; Zhang X; Bi F; Wang D; Zhou X; Li X; Yang Q
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358640
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of the Transcriptome-Wide m6A Methylome in Endometrioid Ovarian Cancer.
Yang L; Chen X; Qian X; Zhang J; Wu M; Yu A
Front Oncol; 2022; 12():844613. PubMed ID: 35280730
[TBL] [Abstract][Full Text] [Related]
16. Emerging Roles of m
Huang W; Kong F; Li R; Chen X; Wang K
Front Oncol; 2022; 12():827956. PubMed ID: 35155260
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of m6A methylation modification in ovarian cancer.
Chang LL; Xu XQ; Liu XL; Guo QQ; Fan YN; He BX; Zhang WZ
Cancer Cell Int; 2021 Dec; 21(1):663. PubMed ID: 34895230
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine RNA modification and its interaction with regulatory non-coding RNAs in colorectal cancer.
Ge Y; Liu T; Wang C; Zhang Y; Xu S; Ren Y; Feng Y; Yin L; Pu Y; Liang G
RNA Biol; 2021 Nov; 18(sup2):551-561. PubMed ID: 34674600
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
